Hims & Hers Health (NYSE:HIMS) Price Target Raised to $35.00 at Piper Sandler

Hims & Hers Health (NYSE:HIMS) had its target price hoisted by Piper Sandler from $24.00 to $35.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

HIMS has been the subject of a number of other research reports. Citigroup upped their price target on shares of Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a report on Tuesday. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $33.40.

Hims & Hers Health Trading Down 22.1 %

Shares of Hims & Hers Health stock opened at $39.95 on Tuesday. The company has a 50 day moving average of $35.62 and a 200-day moving average of $26.25. Hims & Hers Health has a 1-year low of $9.67 and a 1-year high of $72.98. The company has a market cap of $8.73 billion, a PE ratio of 90.79 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the transaction, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 33,513 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at $1,118,296.76. This trade represents a 50.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,097,578 shares of company stock worth $38,080,320. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HIMS. Creative Planning increased its holdings in Hims & Hers Health by 18.1% during the third quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after buying an additional 3,979 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Hims & Hers Health during the third quarter worth about $6,790,000. Dakota Wealth Management purchased a new position in shares of Hims & Hers Health in the third quarter worth about $245,000. Diversify Advisory Services LLC increased its stake in shares of Hims & Hers Health by 14.9% in the third quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock worth $955,000 after purchasing an additional 6,706 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. purchased a new position in shares of Hims & Hers Health in the third quarter worth about $604,000. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.